This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
WASHINGTON: A latest breakthrough treatment for the deadly Hepatitis C virus could soon be available in India as 11 Indian firms have been given licenses by its American manufacturer following an approval from US authorities.
The drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences in its latest breakthrough treatment was last week approved by the US Food and Drug Administration (FDA).
The deadly Hepatitis C virus afflicts as many as 150 million people worldwide and possibly 12 million in India.
This pan-genotypic treatment does not require gene-type testing, eliminating the need for costly gene-type diagnostics, allowing doctors and specialists the ability to prescribe the medicine to anyone who tests positive for Hepatitis C, by taking one pill a day for 8-12 weeks before a cure is achieved.
Note from CD: This is great news for those of you possibly considering medical tourism in India.
Read more at:
http://economictimes.indiatimes.com/articleshow/53075898.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst